• Bet on FIFA
  • Trade
$881.26B
Total marketcap
$72.52B
Total volume
36.05%
BTC dominance
  • Bet on FIFA
  • Trade

Mallinckrodt plc MNKKQ Stock

0.02 USD {{ price }} 0.000000% {{change_pct}}%
Exchange
Other OTC
Market Cap
0 USD
LOW - HIGH [24H]
0.0000 - 0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD

Mallinckrodt plc Price Chart

Mallinckrodt plc MNKKQ Financial and Trading Overview

Mallinckrodt plc stock price 0.02 USD
Previous Close 0.02 USD
Open 0.02 USD
Bid N/A x N/A
Ask N/A x N/A
Day's Range 0.02 - 0.02 USD
52 Week Range 0.001 - 0.36 USD
Volume 290.54K USD
Avg. Volume 344.47K USD
Market Cap 1.69M USD
Beta (5Y Monthly) 2.818627
PE Ratio (TTM) N/A
EPS (TTM) 0 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

MNKKQ Valuation Measures

Enterprise Value 82.67M USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.00076714775
Price/Book (mrq) 0.00330033
Enterprise Value/Revenue 0.037
Enterprise Value/EBITDA 0.105

Trading Information

Mallinckrodt plc Stock Price History

Beta (5Y Monthly) 2.818627
52-Week Change N/A
S&P500 52-Week Change N/A
52 Week High 0.36 USD
52 Week Low 0.001 USD
50-Day Moving Average 0.06 USD
200-Day Moving Average 0.12 USD

MNKKQ Share Statistics

Avg. Volume (3 month) 344.47K USD
Avg. Daily Volume (10-Days) 0 USD
Shares Outstanding 84.72M
Float 78.63M
Short Ratio 10.58
% Held by Insiders 11.18%
% Held by Institutions 0.40%
Shares Short 41.72M
Short % of Float 50.07%
Short % of Shares Outstanding 49.32%

Dividends & Splits

Trailing Annual Dividend Rate N/A
Trailing Annual Dividend Yield N/A
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2021
Most Recent Quarter (mrq) December 31, 2021
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -32.47%
Operating Margin (ttm) 5.21%
Gross Margin 40.36%
EBITDA Margin 35.72%

Management Effectiveness

Return on Assets (ttm) 0.77%
Return on Equity (ttm) -108.58%

Income Statement

Revenue (ttm) 2.21B USD
Revenue Per Share (ttm) 26.08 USD
Quarterly Revenue Growth (yoy) -12.50%
Gross Profit (ttm) 891.7M USD
EBITDA 789M USD
Net Income Avi to Common (ttm) -723500032 USD
Diluted EPS (ttm) -7.869
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 1.34B USD
Total Cash Per Share (mrq) 15.87 USD
Total Debt (mrq) 1.42B USD
Total Debt/Equity (mrq) 453.1 USD
Current Ratio (mrq) 1.189
Book Value Per Share (mrq) 6.06

Cash Flow Statement

Operating Cash Flow (ttm) 455.4M USD
Levered Free Cash Flow (ttm) 855.04M USD

Profile of Mallinckrodt plc

Country United States
State N/A
City Dublin
Address College Business & Technology Park
ZIP 15
Phone 353 1 696 0000
Website https://www.mallinckrodt.com
Industry Drug Manufacturers—Specialty & Generic
Sector(s) Healthcare
Full Time Employees 2778

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Q&A For Mallinckrodt plc Stock

What is a current MNKKQ stock price?

Mallinckrodt plc MNKKQ stock price today per share is 0.02 USD.

How to purchase Mallinckrodt plc stock?

You can buy MNKKQ shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Mallinckrodt plc?

The stock symbol or ticker of Mallinckrodt plc is MNKKQ.

Which industry does the Mallinckrodt plc company belong to?

The Mallinckrodt plc industry is Drug Manufacturers—Specialty & Generic.

How many shares does Mallinckrodt plc have in circulation?

The max supply of Mallinckrodt plc shares is 0.

What is Mallinckrodt plc Price to Earnings Ratio (PE Ratio)?

Mallinckrodt plc PE Ratio is 0.00000000 now.

What was Mallinckrodt plc earnings per share over the trailing 12 months (TTM)?

Mallinckrodt plc EPS is 0 USD over the trailing 12 months.

Which sector does the Mallinckrodt plc company belong to?

The Mallinckrodt plc sector is Healthcare.